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Abstract
Background: PP2Cα is the representative member of the type 2C family of protein phosphatases,
and it has recently been implicated in the regulation of p53-, TGFβ-, cyclin-dependent kinase- and
apoptosis-signaling. To investigate the role of PP2Cα in cell growth and in radio- and
chemosensitivity, wild type and PP2Cα siRNA-expressing MCF7 cells were subjected to several
different viability and cell cycle analyses, both under basal conditions and upon treatment with
radio- and chemotherapy. By comparing the growth of tumors established from both types of cells,
we also evaluated the involvement of PP2Cα in tumorigenesis.
Results: It was found that knockdown of PP2Cα did not affect the proliferation, the clonogenic
survival and the membrane integrity of MCF7 cells. In addition, it did not alter their radio- and
chemosensitivity. For PP2Cα siRNA-expressing MCF7 cells, the number of cells in the G0/G1
phase of the cell cycle was reduced, the induction of the G1 block was attenuated, the number of
cells in G2/M was increased, and the induction of the G2 block was enhanced. The tumorigenic
potential of PP2Cα siRNA-expressing MCF7 cells was found to be higher than that of wild type
MCF7 cells, and the in vivo proliferation of these cells was found to be increased.
Conclusion: Based on these findings, we conclude that PP2Cα is not involved in controlling cell
growth and radio- and chemosensitivity in vitro. It does, however, play a role in the regulation of
the cell cycle, in the induction of cell cycle checkpoints and in tumorigenesis. The latter notion
implies that PP2Cα may possess tumor-suppressing properties, and it thereby sets the stage for
more elaborate analyses on its involvement in the development and  progression of cancer.
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Background
Over the past few decades, significant progress has been
made in understanding the principles of malignant trans-
formation and tumorigenesis. The overexpression and/or
overactivation of protein kinases, for instance, like EGFR,
Her2/neu, Bcr-Abl, c-Met and c-Kit, has been repetitively
shown to be causally linked to the development of malig-
nancy, and it has resulted in the establishment of several
new classes of anticancer agents, like receptor-binding
antibodies and tyrosine kinase inhibitors. The roles and
the functions of the physiological inhibitors of protein
kinases, however, i.e. of protein phosphatases, have been
far less well-documented, and only for a short while now,
significant effort has been put in evaluating the involve-
ment of these enzymes in cancer development and/or
tumor suppression.
The type 2C family of protein phosphatases is a structur-
ally and functionally distinct group of enzymes that cur-
rently contains about 15 different family members [1,2].
As opposed to other serine-threonine specific phos-
phatases, PP2Cs are known to function as monomers, to
depend on bivalent cations for their activity and to be
insensitive to the broad-spectrum phosphatase-inhibitor
okadaic acid [1-3]. Except for the well-known oncopro-
tein PP2Cδ (PPM1D/Wip1) [4-6], all PP2Cs to which
functions have been attributed have been shown to act as
inhibitors of cell growth and cellular stress signaling [2,7-
9].
PP2Cα, for instance, the representative member of the
type 2C family of protein phosphatases, upregulates the
expression and the activity of p53 [10,11], it reduces the
activities of the growth-promoting cyclin-dependent
kinases Cdk2 and Cdk6 [12,13], it negatively affects
TGFβ-signaling [14], it is involved in apoptosis induction
[15,16], and it inhibits the two stress-activated MAPK
pathways JNK and p38 [17,18]. PP2Cβ has also been
shown to activate p53 [11], to inactivate Cdk2 and Cdk6
[12,13], and to inhibit JNK and p38 [17,19]. In addition,
it has been shown to dephosphorylate and activate the
proapoptotic protein BAD, thereby enabling BAD to neu-
tralize the antiapoptotic effects of Bcl-xL [20]. And further-
more, by dephosphorylating and inactivating IKKβ,
PP2Cβ has also been implicated in the attenuation of NF-
kB-mediated antiapoptosis [21]. The recently identified
type 2C phosphatase ILKAP (integrin-linked kinase-asso-
ciated phosphatase) is yet another example of a PP2C
family member with potent growth-suppressive proper-
ties [22]. By dephosphorylating and inactivating the
integrin-linked kinase ILK1, which is involved in the acti-
vation of the oncogenic ILK1-GSK3β-Wnt pathway and
which is known to be overexpressed in several different
human malignancies [23-25], ILKAP has been shown to
be able to inhibit both the proliferation and the malig-
nant transformation of cells [26].
Based on the abovementioned observations, and on the
fact that several others PP2Cs (e.g. PP2Cγ, PP2Cε, PHLPP,
CaMKP and CaMKP-N) have also been implicated in the
inhibition of cell growth and cellular stress signaling [27-
30], we reasoned that type 2C phosphatases may play a
general physiological role in the regulation of these two
processes. To assess the validity of this assumption, we
investigated the involvement of the prototypic type 2C
phosphatase PP2Cα in cell growth, in radio- and chemo-
sensitivity, and in tumorigenicity. Hereto, the prolifera-
tion, the clonogenic survival, the membrane integrity and
the cell cycle distribution of wild type and PP2Cα siRNA-
expressing MCF7 cells were analyzed, both under basal
conditions and upon treatment with different doses of
radio- and chemotherapy. The role of PP2Cα in tumori-
genesis was evaluated by comparing the growth, the cell
cycle distribution and the proliferation rate of tumors
established from both types of cells. It was found that the
knockdown of PP2Cα affected the in vitro growth and the
radio- and chemosensitivity of MCF7 cells only very mod-
erately. It did, however, reflect on their cell cycle distribu-
tion and their tumorigenic potential. In line with the
notions that PP2Cα activates p53 [10,11] and inactivates
Cdk2 and Cdk6 [12,13], these findings suggest that
PP2Cα is involved in cell cycle regulation and in tumor
suppression.
Results
Characterization of PP2Cα-siRNA expressing MCF7 cells
PP2Cα siRNA-expressing MCF7 cells (MCF7-si) were pre-
pared using the pSUPER-Retro vector [31]. The western
blot analyses in Fig. 1A demonstrate that as expected, as
compared to wild type MCF7 cells (MCF7-wt), MCF7-si
cells expressed substantially reduced amounts of PP2Cα.
To investigate the impact of PP2Cα knockdown on cell
growth in vitro, we started off by analyzing the doubling
times of MCF7-wt and MCF7-si cells. As shown in Fig. 1B,
no significant difference was observed between the two
types of cells; 35.6 ± 2.7 h was found for MCF7-wt, as
compared to 33.7 ± 4.3 h for MCF7-si (p = 0.55). Next, the
effect of reducing the expression of PP2Cα on the clono-
genicity of the cells was investigated. Fig. 1C demonstrates
that also in this case, no significant difference could be
observed between MCF7-wt and MCF7-si cells: 2.66 ±
0.28% and 2.72 ± 0.19% of the initial amount of seeded
cells were able to form colonies, respectively (p = 0.70).
Subsequently, the membrane integrity of MCF7-wt and
MCF7-si cells was compared. This was done by trypsiniz-
ing and harvesting confluently growing cells, and by ana-
lyzing the uptake of propidium iodide (PI: a membrane-
impermeable dye that only enters and stains membrane-
damaged and dead cells) by these unfixed cells. As shownMolecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
Page 3 of 14
(page number not for citation purposes)
in the plots in Fig. 1D, three fractions of cells can be gen-
erally discriminated, i.e. viable cells (low PI uptake; M1-
fraction), membrane-damaged cells (intermediate PI
uptake; M2-fraction) and dead cells (high PI uptake; M3-
fraction). Fig. 1D also shows that there was hardly any dif-
ference in membrane integrity between MCF7-wt and
MCF7-si cells. This notion was confirmed by averaging the
data obtained in three independent analyses: of the MCF-
wt cells, 78.2 ± 5.3% were viable, 13.2 ± 3.5% were mem-
brane-damaged and 8.9 ± 2.0% were dead, and of the
MCF-si cells, 79.3 ± 2.3% were viable, 13.4 ± 2.4% were
membrane-damaged and 7.6 ± 1.5% were dead (Fig. 1E; p
> 0.05 for all comparisons). These findings indicate that
the knockdown of PP2Cα does not alter the 'baseline-via-
bility' of MCF7 cells.
Effect of PP2Cα knockdown on cell cycle distribution
Next, confluently growing MCF7-wt and MCF7-si cells
were trypsinized, harvested, fixed, labeled with PI, and
subjected to cell cycle analysis. Fig. 1F shows that the
knockdown of PP2Cα resulted in an increase in the
number of cells in G2/M. This observation was confirmed
by pooling the data obtained in three independent analy-
ses; 22.7 ± 3.7% of the MCF7-si cells were in G2/M, as
compared to 12.0 ± 1.2% for MCF7-wt cells (p = 0.009;
Table 1). Table 1 also demonstrates that the knockdown
of PP2Cα resulted in a reduction of the number of cells in
G0/G1; 44.9 ± 2.4% of the MCF7-si cells were in G0/G1,
as compared to 54.5 ± 1.5% for MCF7-wt (p = 0.004). The
percentages of cells in the S phase were comparable (Table
1; p = 0.30).
Characterization of wild type and PP2Cα siRNA-expressing MCF7 cells Figure 1
Characterization of wild type and PP2Cα siRNA-expressing MCF7 cells. A: Western blot analysis of the expression 
of PP2Cα and Actin in wild type (MCF7-wt) and PP2Cα knockdown (MCF7-si) cells. B: Doubling time of MCF7-wt and MCF7-
si cells. Values represent average ± SD (n = 3). C: Clonogenicity of MCF7-wt and MCF7-si cells. Values represent average ± SD 
(n = 5). D: Representative FACS analyses of the uptake of propidium iodide (PI) by confluently growing MCF7-wt and MCF7-si 
cells. The uptake of PI was used to determine the membrane integrity of the (unfixed) cells. M1: viable cells. M2: membrane-
damaged cells. M3: dead cells. E: Quantification of the viability of MCF7-wt and MCF7-si cells. The amount of viable cells (M1 
fraction) was determined by pooling the data obtained in three independent analyses. Values represent average ± SD. F: Repre-
sentative images of the cell cycle distribution of confluently growing MCF7-wt and MCF7-si cells. G: Representative images of 
the cell cycle distribution of MCF7-wt and MCF7-si cells at various time points after trypsination and (re-) seeding.Molecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
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Subsequently, the cell cycle distribution of the two types
of cells was investigated at various time points after
trypsinization and (re-) seeding. Fig. 1G and Table 1 show
that also upon trypsinization, MCF7-si cells presented
with increased amounts in G2/M and with decreased per-
centages in G0/G1. The fact that the number of MCF7-si
cells in G2/M was found to be higher at all time points
post reseeding (p < 0.05 for all, except for 48 h; Table 1)
indicates that PP2Cα can be expected to play a general
physiological role in the regulation of the G2-to-M transi-
tion. The percentages in G0/G1 showed a different pat-
tern; at the early (6 and 12 h) and late (72 h) time points
post reseeding, the number of cells in G0/G1 was signifi-
cantly lower for MCF7-si. At 24 and 48 h, however, their
percentages in G0/G1 were significantly higher. This sug-
gests that in cells lacking PP2Cα, the induction of the G0/
G1 arrest in response to trypsinization is delayed (peak at
24–48 h for MCF7-si vs. at 6–12 h for MCF7-wt). Together
with the notion that the maximal extent of the G0/G1
arrest was lower for MCF7-si cells (59% vs. 74%; Table 1),
this observation indicates that PP2Cα likely also plays a
role in the induction the G1 block and in the G1-to-S tran-
sition.
Effect of PP2Cα knockdown on radiosensitivity
The role of PP2Cα in regulating radiosensitivity was inves-
tigated by exposing wild type and siRNA-expressing MCF7
cells to different doses of 60Cobalt γ-radiation, and by sub-
sequently subjecting them to three different viability
assays. The Sulphorhodamine B (SRB) assay was used to
assess cellular proliferation [32]. Fig. 2A shows that there
was no significant difference in proliferation between
MCF7-wt and MCF7-si cells in response to radiotherapy.
Fig. 2B shows that also when analyzing the clonogenic
survival of the cells, no difference could be observed
between the two types of cells. Analysis of the membrane
integrity of the cells in response to radiotherapy, on the
other hand, did point towards a difference between wild
type and PP2Cα knockdown cells; as shown in Fig. 2C, as
expected, the percentages of physiologically intact MCF7-
wt cells decreased as I) the time post-treatment increased
and as II) the dose of radiotherapy increased; 48 h after 6
and 12 Gy, for instance, the normalized viabilities were
92.0 ± 2.2% and 77.0 ± 4.4%, respectively. For MCF7-si
cells, on the other hand, the degree of membrane-damage
did not correlate to the time post treatment and to the
dose of radiotherapy applied; 48 h after 6 and 12 Gy, the
normalized viabilities were 94.9 ± 0.7% (p = 0.30) and
93.8 ± 2.6% (p = 0.004), respectively. These findings indi-
cate that the knockdown of PP2Cα does not alter the pro-
liferation and the clonogenic survival of MCF7 cells in
response to radiotherapy, but that it does reflect on their
membrane integrity.
The impact of PP2Cα knockdown on radiotherapy-
induced cell cycle changes was investigated by exposing
the MCF7-wt and the MCF7-si cells to 0, 2, 4, 6, and 12 Gy
of 60Cobalt γ-radiation, and by analyzing their cell cycle
distribution 24, 48 and 72 h later. Fig. 2E shows represent-
ative results obtained at 48 h after radiotherapy. As can be
seen, the only two differences between the two types of
cells were that I) the number of sham-irradiated control
cells in the G2/M phase again tended to be higher for
MCF7-si (in line the data obtained under basal conditions
(Fig. 1F and Table 1)), and that II) the induction of the G2
block in response to high doses of radiotherapy was
stronger for MCF7-si.
Quantitative analysis using the Multicycle algorithm con-
firmed that under control conditions (i.e. at 24 h after
exposure to 0 Gy), the percentage in G2/M was signifi-
cantly higher for PP2Cα knockdown cells (14.2 ± 0.7%
for MCF7-si, as compared to 9.2 ± 1.5% (p = 0.007) for
MCF7-wt; Table 2). It also again showed that this increase
in G2/M was paralleled by a decrease in G0/G1; 55.6 ±
0.5% were found in the G0/G1 phase for MCF-si, as com-
Table 1: Cell cycle analysis of wild type and PP2Cα siRNA-expressing MCF7 cells.
Time (hours 
post 
trypsination)
MCF7-wt MCF7-si
G0/G1 S G2/M G0/G1 S G2/M
Control 54.5 ± 1.5 33.5 ± 0.4 12.0 ± 1.3 44.9 ± 2.4 * 32.4 ± 1.6 22.7 ± 3.7 *
6 74.0 ± 0.5 17.3 ± 0.2 8.6 ± 0.4 50.2 ± 2.8 * 34.4 ± 2.4 * 16.1 ± 4.2 *
12 74.1 ± 0.2 16.7 ± 0.8 9.2 ± 0.7 46.1 ± 3.6 * 33.5 ± 3.1 * 20.4 ± 6.7 *
24 48.0 ± 0.9 41.7 ± 0.4 10.3 ± 0.9 57.8 ± 2.7 * 23.8 ± 3.5 * 18.4 ± 1.1 *
48 48.4 ± 0.7 39.9 ± 0.4 11.6 ± 0.8 59.4 ± 4.8 * 25.1 ± 0.3 * 15.5 ± 4.9
72 51.9 ± 0.5 34.6 ± 0.5 13.5 ± 0.3 46.3 ± 2.7 * 31.3 ± 1.0 * 21.8 ± 2.5 *
Multicycle algorithm-based quantification of the amounts of MCF7-wt and MCF7-si cells in the G0/G1, the S and the G2/M phase of the cell cycle. 
Results are shown both for confluently growing control cells and for cells analyzed at various time points after trypsination and (re-) seeding. Values 
represent average ± SD (n = 3). * Indicates p < 0.05 vs. MCF-wt.Molecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
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pared to 61.3 ± 0.5% for MCF-wt (p = 0.0001). These
notions strengthen the conclusion that PP2Cα is involved
in cell cycle regulation.
Overall, the observed radiotherapy-induced cell cycle
changes were in accordance with the literature (33-35), as
cells generally (attempt to) repair radiation-induced DNA
damage in the two gap phases of the cycle, i.e. in G1 and
G2; at lower doses of radiotherapy, both MCF7-wt and
MCF7-si cells presented with increases in G0/G1, and at
higher doses, both presented with increases in G2/M
(Table 2). When focusing on the latter, two obvious differ-
ences could be noted between the two types of cells. First,
a strong induction of the G2 block presented earlier on in
time in the MCF7-si cells; at 24 h, MCF7-si cells already
presented with a strong arrest in G2/M upon exposure to
12 Gy (41.8 ± 0.8%), whereas MCF7-wt cells only dis-
played a slight induction of the G2 block at this time point
(20.6 ± 0.5%; p < 0.0001). And second, the overall extent
of the G2 block was higher for MCF7-si; 48 h after 12 Gy,
for instance, 48.6 ± 0.4% was found in G2/M for MCF7-si,
as compared to 37.3 ± 3.1% for MCF7-wt (p = 0.003;
Table 2). These observations indicate that the knockdown
of PP2Cα affects the radiotherapy-induced changes in the
cell cycle distribution of MCF7 cells both in a time-
dependent manner (earlier induction of the G2 block)
and in a concentration-dependent manner (stronger
induction of the G2 block).
Evaluation of the radiosensitivity of wild type and PP2Cα siRNA-expressing MCF7 cells Figure 2
Evaluation of the radiosensitivity of wild type and PP2Cα siRNA-expressing MCF7 cells. A: Effect of different doses 
of 60Cobalt γ-radiation on the proliferation of MCF7-wt and MCF7-si cells. Values represent average ± SD (n = 4). B: Effect of 
radiotherapy on the clonogenicity of MCF7-wt and MCF7-si cells. Values represent average ± SD (n = 4). C and D: Quantifica-
tion of the effect of radiotherapy on the viability (i.e. the membrane integrity) of MCF7-wt and MCF7-si cells. The viability was 
determined by means of FACS analysis. Values represent average ± SD (n = 3). E: Representative images of the cell cycle distri-
bution of MCF7-wt and MCF7-si cells at 48 h after treatment with radiotherapy.Molecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
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Effect of PP2Cα knockdown on chemosensitivity
To investigate the impact of PP2Cα knockdown on chem-
osensitivity, wild type and siRNA-expressing MCF7 cells
were exposed to doxorubicin and subjected to the three
abovementioned viability assays. Figs. 3A and 3B demon-
strate that at doxorubicin concentrations of 0.1–10 µM,
no difference in proliferation could be observed between
the two types of cells, neither when they were pulse-incu-
bated (i.e. for 24 h; Fig. 3A), nor when they were incu-
bated continuously (i.e. for 120 h; Fig. 3B). Next, the
impact of doxorubicin on the clonogenic survival of wild
type and PP2Cα knockdown cells was evaluated. As
shown in Fig. 3C, also in this case, no difference in
response to chemotherapeutic treatment could be
observed between the two types of cells. To exclude the
possibility that the observed lack of an altered chemosen-
sitivity was drug-specific, we also evaluated the clono-
genicity of the cells in response to gemcitabine. As shown
in Fig. 3D, however, also upon treatment with gemcitab-
ine, no difference in clonogenic survival could be detected
between wild type and PP2Cα knockdown cells. This find-
ing indicates that the observed lack of a differential chem-
osensitivity was not specific for doxorubicin, and it
suggests that MCF7-wt and MCF-si cells are equally sensi-
tive towards chemotherapeutic treatment. Subsequently,
as for radiotherapy, we then also investigated the impact
of chemotherapy on the membrane integrity of MCF7-wt
and MCF7-si cells. Figs. 3E and 3F present the pooled
results of three independent analyses, and they demon-
strate that there was hardly any difference in chemosensi-
tivity between the two types of cells; at 24 h, the uptake of
PI was slightly higher for MCF7-si, at 48 h, the viability of
the cells was identical, and at 72 h, the degree of mem-
brane-damage was slightly higher for MCF7-wt. In line
with information obtained in the SRB and the CFA analy-
ses, these findings demonstrate that the knockdown of
PP2Cα does not alter the chemosensitivity of MCF7 cells.
To assess the effects of the knockdown of PP2Cα on the
chemotherapy-induced cell cycle changes, MCF7-wt and
MCF7-si cells were incubated with doxorubicin concen-
trations ranging from 1 to 20 µM and subjected to cell
cycle analysis 24, 48 and 72 h later. As shown in Fig. 3G
and Table 3, three more or less obvious differences could
be observed between the two cell types: I) whereas the
former presented with increases in the number of cells in
both G0/G1 and G2/M at 24 and 48 h after incubation
with 1 µM of doxorubicin, the latter presented with
decreases in G0/G1 and, at 48 h, with a much more sub-
stantial increase in G2/M. II) In the MCF7-si cells, a strong
induction of the G2 block upon exposure to 1 µM of dox-
orubicin presented earlier on time (at 48 h) than in the
MCF7-wt cells (at 72 h). III) In the MCF7-si cells, the max-
imal induction of the G2 block was lower than that in
MCF7-wt cells (57.8 ± 1.5% vs. 63.2 ± 1.1%). These results
demonstrate that without affecting the proliferation, the
clonogenic survival and the membrane integrity of MCF7
cells, the knockdown of PP2Cα does reflect, at least to
some extent, on their cell cycle distribution.
Tumorigenicity of wild type and PP2Cα knockdown MCF7 
cells
To address the involvement of PP2Cα in tumorigenesis, 1
* 107 MCF-wt and MCF7-si cells were inoculated subcuta-
Table 2: Cell cycle analysis of wild type and PP2Cα siRNA-expressing MCF7 cells upon treatment with radiotherapy.
MCF7-wt MCF7-si
Time (h) RT Dose (Gy) G0/G1 S G2/M G0/G1 S G2/M
24 0 61.3 ± 0.5 29.5 ± 1.1 9.2 ± 1.5 55.6 ± 0.5 * 30.3 ± 0.4 14.2 ± 0.7 *
2 68.3 ± 0.2 21.8 ± 0.4 9.9 ± 0.4 61.4 ± 1.3 * 25.4 ± 1.1 * 13.2 ± 0.5 *
4 71.6 ± 0.2 16.7 ± 0.2 11.7 ± 0.3 67.4 ± 6.2 * 25.0 ± 5.7 * 7.5 ± 0.9 *
6 70.9 ± 0.6 14.0 ± 0.4 15.1 ± 0.7 77.5 ± 0.9 * 9.2 ± 1.5 * 13.3 ± 0.6 *
12 66.8 ± 0.5 12.6 ± 0.3 20.6 ± 0.5 54.8 ± 0.9 * 3.4 ± 0.3 * 41.8 ± 0.8 *
48 0 61.5 ± 0.6 35.4 ± 1.4 12.7 ± 1.3 61.2 ± 1.8 * 31.0 ± 1.2 * 12.0 ± 0.4
2 62.9 ± 8.0 28.1 ± 5.5 9.0 ± 2.5 69.2 ± 0.4 21.4 ± 0.2 9.4 ± 0.4
4 75.9 ± 6.7 15.8 ± 8.0 8.2 ± 1.3 77.9 ± 0.2 11.3 ± 0.4 10.8 ± 0.6 *
6 79.2 ± 1.0 7.4 ± 2.8 13.7 ± 3.4 74.4 ± 0.9 * 5.8 ± 0.4 19.8 ± 1.3 *
12 55.3 ± 1.1 7.2 ± 3.7 37.3 ± 3.1 48.8 ± 0.4 * 2.6 ± 0.4 48.6 ± 0.4 *
72 0 51.1 ± 1.3 42.4 ± 2.0 6.4 ± 1.2 54.0 ± 2.6 33.6 ± 0.2 * 12.6 ± 2.9 *
2 61.1 ± 0.3 26.6 ± 1.1 12.3 ± 1.0 61.9 ± 0.6 24.7 ± 0.1 * 13.4 ± 0.6
4 65.1 ± 1.7 21.2 ± 1.1 13.7 ± 1.3 66.2 ± 0.9 18.5 ± 0.9 * 15.3 ± 1.5
6 66.4 ± 0.6 14.7 ± 0.8 18.9 ± 0.9 68.4 ± 0.6 * 13.8 ± 0.4 17.9 ± 0.1
12 51.7 ± 0.7 8.1 ± 0.6 40.3 ± 0.2 54.9 ± 0.3 * 6.4 ± 0.8 38.7 ± 0.2 *
Multicycle algorithm-based quantification of the amounts of MCF7-wt and MCF7-si cells in the G0/G1, the S and the G2/M phase of the cell cycle at 
24, 48 and 72 h after treatment with the indicated doses of radiotherapy. Values represent average ± SD (n = 3). * Indicates p < 0.05 vs. MCF-wt.Molecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
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neously (s.c.) into both hind limbs of immunodeficient
nude mice. Neither the MCF7-wt cells, however, nor the
MCF7-si cells turned out to be able to develop tumors
under physiological conditions (Table 4). Based on the
notion that MCF7 cells are hormone-dependent breast
cancer cells, and on the assumption that their in vivo
growth therefore likely depends on the levels of circulat-
ing hormones, we next implanted estrogen-containing
Evaluation of the chemosensitivity of wild type and PP2Cα siRNA-expressing MCF7 cells Figure 3
Evaluation of the chemosensitivity of wild type and PP2Cα siRNA-expressing MCF7 cells. A and B: Effect of differ-
ent doses of doxorubicin on the proliferation of MCF7-wt and MCF7-si cells. The cells were either exposed to the drug for 24 
h (A) or continuously (B). Values represent average ± SD (n = 3). C: Effect of doxorubicin on the clonogenicity of MCF7-wt 
and MCF7-si cells. Values represent average ± SD (n = 3). D: Effect of gemcitabine on the clonogenicity of MCF7-wt and 
MCF7-si cells. Values represent average ± SD (n = 3). E and F: Quantification of the effect of doxorubicin on the viability (i.e. 
the membrane integrity) of MCF7-wt and MCF7-si cells. The viability was determined by means of FACS analysis. Values repre-
sent average ± SD (n = 3). G: Representative images of the cell cycle distribution of MCF7-wt and MCF7-si cells after 48 h of 
doxorubicin treatment.Molecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
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hormone pellets into 8 nude mice. Ten days after the
implantation of the pellets, 1 * 107 MCF7-wt and MCF7-
si cells were again inoculated s.c. into both hind limbs of
the animals. As shown in Table 4, in one animal injected
with MCF7-si cells, a tumor had formed (8 × 11 mm at
day 35). In the other three animals injected with MCF7-si
cells, and in all four animals injected with MCF7-wt cells,
no tumors had developed. In order to increase the
number of malignant cells remaining at the site of inocu-
lation, we subsequently suspended 1 * 107  cells in
Matrigel and inoculated them s.c. into 10 nude mice. Up
to three weeks post inoculation, 2–3 mm sized tumors (or
rather, semi-palpable suspensions of tumor cells) could
be observed in all animals. After this time point, however,
they disappeared one after the other, and at day 50, no
tumors had developed (Table 4). Finally, in an ultimate
attempt to improve the tumorigenic potential of the two
types of MCF7 cells, the estrogen-containing hormone
pellets were combined with Matrigel; hereto, 1 * 107 wild
type and PP2Cα knockdown cells were suspended in
Matrigel, and they were inoculated into mice that had
been implanted with pellets 10 days before. Approxi-
mately 3 weeks after inoculation, several animals, espe-
cially those injected with MCF7-si cells, started to present
with signs of tumor growth. As shown in Figs. 4A and 4B,
from this day on, several MCF7-si tumors kept on growing
steadily, reaching sizes of e.g. 13 × 14 or 10 × 12 mm by
day 37. The growth curves in Fig. 4A furthermore demon-
strate that a substantially smaller fraction of the animals
inoculated with MCF7-wt cells turned out to be able to
form tumors (4 out of 8, as compared to 9 out of 10 for
MCF7-si), and they also exemplify that those MCF7-wt
tumors that did grow, grew much slower than did the
MCF7-si tumors; 37 days after inoculation, the largest
MCF7-wt tumor was 7 × 10 mm, as compared to 12 × 19
mm for MCF7-si (Figs. 4A and 4B). These findings suggest
that, at least under certain conditions, the knockdown of
PP2Cα increases the tumorigenicity of MCF7 cells.
To validate that the MCF7-wt and MCF7-si tumors that
had developed upon the combined implementation of
the hormone pellets and Matrigel presented with physio-
Table 3: Cell cycle analysis of wild type and PP2Cα siRNA-expressing MCF7 cells upon treatment with chemotherapy.
MCF7-wt MCF7-si
Time (h) Dox Dose 
(µM)
G0/G1 S G2/M G0/G1 S G2/M
24 0 53.6 ± 0.5 33.3 ± 1.2 13.1 ± 0.3 56.6 ± 0.5 * 29.7 ± 0.6 * 13.7 ± 0.9
1 74.8 ± 0.9 8.0 ± 0.6 17.2 ± 0.3 53.9 ± 0.6 * 30.7 ± 1.0 * 15.4 ± 1.3
2.5 50.4 ± 0.7 4.1 ± 0.8 45.5 ± 1.5 52.1 ± 0.9 5.0 ± 2.7 42.8 ± 1.9
5 45.1 ± 0.2 6.4 ± 0.2 48.5 ± 0.1 51.5 ± 1.6 * 5.1 ± 2.4 43.4 ± 0.9 *
10 38.9 ± 1.3 29.5 ± 0.8 31.6 ± 0.8 41.3 ± 0.3 * 32.5 ± 1.6 * 26.2 ± 1.5 *
20 40.8 ± 1.8 31.3 ± 2.5 27.8 ± 1.3 54.9 ± 1.4 * 30.2 ± 0.5 14.9 ± 1.4 *
48 0 61.5 ± 0.6 29.1 ± 1.0 9.4 ± 0.7 61.2 ± 1.8 29.5 ± 1.7 11.2 ± 0.1 *
1 71.4 ± 3.5 8.9 ± 1.7 19.7 ± 5.2 52.2 ± 2.7 * 2.5 ± 1.2 * 45.3 ± 1.7 *
2.5 35.7 ± 1.3 3.9 ± 0.3 60.4 ± 1.0 58.3 ± 5.8 * 3.2 ± 0.6 38.5 ± 5.3 *
5 31.7 ± 0.5 5.2 ± 1.6 63.2 ± 1.1 49.6 ± 1.0 * 2.5 ± 0.7 47.8 ± 0.4 *
10 30.3 ± 1.0 23.6 ± 0.8 46.1 ± 0.7 44.0 ± 1.7 * 8.4 ± 0.6 * 47.6 ± 2.3
20 33.2 ± 1.8 48.6 ± 7.7 18.3± 9.4 50.3 ± 0.8 * 43.4 ± 2.4 6.4 ± 1.6
72 0 71.9 ± 1.7 22.8 ± 0.7 5.4 ± 1.3 59.2 ± 0.9 * 30.4 ± 1.6 * 10.5 ± 0.6 *
1 52.5 ± 7.2 3.1 ± 1.9 44.4 ± 8.9 47.4 ± 7.3 0.5 ± 0.9 52.1 ± 8.2
2.5 46.4 ± 1.2 0.5 ± 0.5 53.3 ± 2.0 41.3 ± 2.6 * 1.9 ± 3.0 56.8 ± 1.8
5 38.8 ± 0.3 0.1 ± 0.1 61.3 ± 0.3 40.4 ± 0.8 * 1.8 ± 1.6 57.8 ± 1.5 *
10 34.1 ± 0.7 16.4 ± 1.7 49.5 ± 2.3 37.5 ± 1.5 * 3.5 ± 2.5 * 57.1 ± 2.6 *
20 32.8 ± 2.8 39.9 ± 1.8 27.3 ± 1.8 N.Q. N.Q. N.Q.
Multicycle algorithm-based quantification of the amounts of MCF7-wt and MCF7-si cells in the G0/G1, the S and the G2/M phase of the cell cycle at 
24, 48 and 72 h after treatment with the indicated doses of doxorubicin. Values represent average ± SD (n = 3). N.Q. (Not Quantifiable) indicates 
that multicycle algorithm failed to attribute the cells to a certain cell cycle phase. * Indicates p < 0.05 vs. MCF-wt.
Table 4: Overview over the experiments evaluating the 
tumorigenicity of the MCF7-wt and MCF7-si cells.
Experiment Hormone Pellets Matrigel MCF-wt MCF-si
1 - - 0/10 0/8
2 +- 0 / 8 1 / 8
3 - + 0/10 0/10
4 + + 4/8 9/10
The number of tumors that had developed under control conditions 
(Exp. 1), upon the implantation of estrogen-containing hormone pellets 
(Exp. 2), upon the use of Matrigel (Exp. 3), and upon the combined 
implementation of estrogen-containing hormone pellets and Matrigel 
(Exp. 4) are presented.Molecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
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Evaluation of the tumorigenic potential of wild type and PP2Cα siRNA-expressing MCF7 cells Figure 4
Evaluation of the tumorigenic potential of wild type and PP2Cα siRNA-expressing MCF7 cells. A: Tumor growth 
curves obtained for subcutaneously inoculated MCF7-wt and MCF7-si cells upon the combined implementation of estrogen-
containing hormone pellets and Matrigel. The values indicate the individual tumor sizes at day 37. B: Exemplary images of 
MCF7-wt and MCF7-si tumors at day 37 post inoculation. C: Analysis of the expression of PP2Cα in MCF7-wt and MCF7-si 
tumors. Magnification 200×. D: Representative images of the cell cycle distribution of MCF7-wt and MCF7-si tumors. Left yel-
low peak: G0/G1 fraction of the aneuploid tumor cells (i.e. the MCF7 cells). Right yellow peak: G2/M fraction of the aneuploid 
tumor cells. Dashed blue area: S phase fraction of the aneuploid tumor cells. Red peak: G1 fraction of the diploid host cells (e.g. 
mouse fibroblasts and endothelial cells). Blue peak: Necrotic cells. E: Multicycle algorithm-based quantification of the cell cycle 
distribution of MCF7-wt and MCF7-si tumors. Values represent average ± SD (n = 3). F: Analysis of the expression of the pro-
liferation marker Ki-67 in MCF7-wt and MCF7-si tumors. Magnification 200×. G: Representative FACS analyses of the incorpo-
ration of the proliferation marker BrdU in MCF7-wt and MCF7-si tumors. H: Quantification of the amount of BrdU-positive 
cells in MCF7-wt and MCF7-si tumors. Values represent average ± SD (n = 3). * Indicates p < 0.05.
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logical and attenuated amounts of PP2Cα, respectively,
the expression of PP2Cα was analyzed immunohisto-
chemically. As shown in the images in Fig. 4D, in MCF7-
wt tumors, substantial amounts of PP2Cα could be
detected. In MCF7-si tumors, on the other hand, hardly
any expression of PP2Cα could be observed. This finding
indicates that even after having grown in vivo for more
than five weeks, the siRNA-producing pSUPER-Retro vec-
tor was still fully functional.
To evaluate how the knockdown of PP2Cα reflects on the
in vivo cell cycle distribution of the MCF7 cells, PFA-fixed
tumor material was subjected to cell cycle analysis. As
shown in Figs. 4D and 4E, in line with the in vitro studies,
the number of MCF7-si cells in G0/G1 tended to be
decreased and the amounts in G2/M tended to be
increased. In addition, the percentages in S appeared to be
increased. Quantification using the Multicycle algorithm,
however, demonstrated that neither of the three differ-
ences was statistically significant (Fig. 4E).
To investigate the impact of PP2Cα knockdown on cell
growth in vivo, the expression of the proliferation marker
Ki-67 was analyzed in MCF7-wt and MCF7-si tumors. As
shown in Fig. 4F, no difference in the intensity of Ki-67
staining could be observed. The pattern of Ki-67 staining,
however, was repetitively found be different, with MCF7-
si tumors being stained more homogenously than MCF7-
wt tumors; for the former, virtually all areas investigated
displayed expression of the proliferation marker, whereas
for the latter, only certain areas clearly displayed positive
signals.
To quantitatively confirm this notion, we finally also
assessed cell growth in vivo by means of BrdU staining.
BrdU is a synthetic thymidine analogue that is incorpo-
rated into DNA during replication and that is routinely
used as a marker for cells in the S phase, i.e. for proliferat-
ing cells. As shown in the exemplary FACS analyses in Fig.
4G, the incorporation of BrdU tended to be higher for
PP2Cα knockdown tumors. Quantitative analyses con-
firmed that the extent of BrdU incorporation was signifi-
cantly higher for MCF7-si (41.3 ± 4.7%, vs. 31.9 ± 2.4%
for MCF7-wt; p = 0.036; Fig. 4H). Together with the
notion that the staining of Ki-67 was more homogenous
for MCF7-si, this finding indicates that in PP2Cα knock-
down tumors, a higher proportion of the cells contributes
to the overall growth of the tumors, and it explains, at
least in part, the more effective and the more rapid growth
of these tumors.
Discussion
Ever more interesting features, phenotypes and potential
clinical applications are being ascribed to the type 2C fam-
ily of protein phosphatases. PP2Cα, for instance, has been
shown to activate p53 [10], to inhibit MDM2 [11], to
inactivate Cdk2 and Cdk6 [12,13], to attenuate TGFβ-sig-
naling [14] and to be positively involved in apoptosis
induction [15,16]. PP2Cβ has also been shown to activate
p53 [11], to inhibit MDM2 [11], and to inactivate Cdk2
and Cdk6 [12,13]. Furthermore, it has been shown to acti-
vate the proapoptotic protein BAD [20], and to attenuate
NF-kB-mediated antiapoptosis [21]. In addition to PP2Cα
and PP2Cβ, the recently identified PP2Cs ILKAP and
PHLPP have also been implicated in growth regulation;
the former has been shown to negatively affect prolifera-
tion and malignant transformation [22], and the latter to
promote apoptosis and to inhibit tumor growth [29].
Based on these notions, it seems to be reasonable to
assume that these four type 2C phosphatases might act as
tumor suppressor proteins.
Conversely however, a substantial amount of evidence
exists indicating that PP2Cδ (PPM1D/Wip1) is an onco-
gene; it has been shown to inhibit the activity of four dif-
ferent tumor suppressor proteins (p53, ATM, INK4A and
ARF), to inhibit the function of the checkpoint kinases
Chk1 and Chk2, to negatively affect base-excision repair
and to be overexpressed in various different human malig-
nancies, including e.g. breast carcinomas, ovarian carcino-
mas, neuroblastomas and medulloblastomas [2,4-6].
These notions exemplify that the properties of PP2Cs can-
not be generalized, and they emphasize that in order to be
able to attribute clinical significance to the functions of
type 2C phosphatases in cell growth, in tumorigenesis and
in anticancer therapy, each individual family member
needs to be characterized in proper detail.
Here, we have therefore set out to investigate the involve-
ment of the prototypic type 2C phosphatase PP2Cα in
growth regulation, in radio- and chemosensitivity, and in
tumorigenicity. It was shown that under 'physiological'
conditions, the doubling time, the clonogenicity and the
membrane integrity were comparable for MCF7-wt and
MCF7-si cells (Fig. 1), which indicates that the knock-
down of PP2Cα does not affect cell growth in vitro. This
notion was confirmed by showing that also upon treat-
ment with different doses of radio- and chemotherapy,
the proliferation, the clonogenic survival and the mem-
brane integrity were comparable for wild type and PP2Cα
knockdown cells (Figs. 2 and 3).
A large set of cell cycle analyses subsequently demon-
strated that the knockdown of PP2Cα did reflect on the
cell cycle distribution of the MCF7 cells; a significantly
lower percentage (or a significantly shorter residence
time) in G0/G1, and a significantly higher percentage (or
a significantly longer residence time) in G2/M were found
for MCF7-si cells (Fig. 1 and Table 1). These findings are
in line with the results published by Chen et al, who haveMolecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
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shown that in Drosophila S2 cells, the RNAi-mediated
knockdown of CG1906 (i.e. Drosophila PP2C) results in
a reduction of the number of cells in G1, and in an
increase in the percentages in G2 [36]. In addition, our
observations are in line with the data provided by Guille-
main et al, who have recently demonstrated that upon the
reintroduction of the yeast PP2C gene Ptc2, the number of
cells arresting in G2/M after HO endonuclease treatment
(which induces DNA double-strand breaks) was signifi-
cantly lower than that of cells transfected with dysfunc-
tional Ptc2 or with empty vector [37].
Several different mechanisms can be envisioned by which
the knockdown of PP2Cα affects the cell cycle. Plausible
explanations for the enhanced G1-to-S transition are: I)
less PP2Cα is available for dephosphorylating Cdk2
[12,13], which results in an increase in the activity of the
Cyclin E – Cdk2 complex, and which thereby promotes
entry into the S phase [38-40]. II) Less PP2Cα is available
for dephosphorylating Cdk2 [12,13], which results in an
increase in the activity of the Cyclin E – Cdk2 complex.
Activated Cyclin E – Cdk2 then provides relief from the
Rb-mediated repression of the expression of Cyclin A
[41,42], thereby enabling Cyclin A to complex with Cdk2
and to induce G1-to-S transition [39,40,43,44]. III) Less
PP2Cα is available for dephosphorylating Cdk6 [12,13],
which results in an increase in the activity of the Cyclin D
– Cdk6 complex. Active Cyclin D – Cdk6 then phosphor-
ylates and inactivates Rb [45-47], thereby enhancing the
expression of Cyclin A [41,42] and Cyclin E [48,49], and
thereby promoting G1-to-S transition [38-44]. And
finally, IV) less PP2Cα is available for inhibiting MDM2
[11]. More MDM2 results in less p53, in less p21, in a
reduction of the p21-mediated repression of the activity of
the Cyclin E – Cdk2 complex [50,51], and in an induction
of the G1-to-S transition [38-40].
The observation that the knockdown of PP2Cα induces
the transition from G1 to S was confirmed by evaluating
the cell cycle distribution of MCF7-wt and MCF7-si cells
upon trypsinization. As most 'normal' cells, MCF7-wt
cells presented with substantially increased amounts in
G0/G1 at the early time points post trypsinization (i.e. at
6 and 12 h; Table 1). MCF7-si cells, on the other hand,
failed to induce a G0/G1 arrest upon trypsinization (Table
1), and also upon chemotherapy, they did not arrest in
G0/G1 as effectively as MCF7-wt cells (Fig. 3 and Table 3).
Remarkably, however, upon exposure to ionizing radia-
tion, MCF7-si cells did arrest in G0/G1 (Fig. 2E). A poten-
tial explanation for this discrepancy is that different
signaling pathways are induced by anticancer agents and
ionizing radiation in MCF7 cells [52], and that such differ-
ences result in a different cell cycle behavior and in an
altered induction of cell cycle checkpoints.
Another obvious difference between MCF7-wt and MCF7-
si cells was found to be in the number of cells in G2/M;
both under basal conditions and upon trypsinization, the
percentages of MCF7-si cells in the G2/M phase (or their
residence time in G2/M) were significantly higher than
those of MCF7-wt cells (Fig. 1 and Table 1). In addition,
the induction of the G2/M arrest in response to radio- and
chemotherapy was found to be affected by the knock-
down PP2Cα. In both cases, it was affected in a time-
dependent manner and in a concentration-dependent
manner; for radiotherapy, the knockdown of PP2Cα
resulted in an earlier and in a stronger induction of the G2
block (Fig. 2 and Table 2), whereas for chemotherapy, it
resulted in an earlier and in a less strong induction (Fig. 3
and Table 3). These findings indicate that besides being
involved in the G1-to-S transition and the G1 arrest,
PP2Cα is also involved in the G2-to-M transition and the
G2 arrest.
In the final set of experiments, the tumorigenicity of
MCF7-wt and MCF7-si cells was compared. As both types
of cells failed to develop tumors under physiological con-
ditions, estrogen-containing hormone pellets and
Matrigel were used. The former were implemented
because the in vivo growth of MCF7 cells likely depends
on the levels of circulating hormones, and the latter was
used because it is known to prolong the retention time of
(tumor) cells at the site of inoculation. Only upon the
combined implementation of the hormone pellets and
Matrigel, significant numbers of tumors were obtained for
both types of cells; for MCF7-si, tumors grew in 9 out of
10 cases, and for MCF7-wt, tumors developed in 4 out of
8 cases (Fig. 4 and Table 4). In addition to the higher pro-
portion of tumors that developed for MCF7-si, these
tumors were also found to be growing more rapidly than
their wild type counterparts. These findings were con-
firmed by showing that in MCF7-si tumors, the expression
of the proliferation marker Ki-67 was more abundant and
the incorporation of the S-phase marker BrdU was
increased (Fig. 4). Our results thus demonstrate that in
vivo, MCF7-si cells proliferate more effectively and more
rapidly than MCF7-wt cells, and together with the notions
that it activates p53 [10,11], inactivates Cdk2 and Cdk6
[12,13], inhibits TGFβ signaling [14] and induces
(endothelial cell) apoptosis [15,16], they suggest that
PP2Cα may possess tumor-suppressing properties.
To validate this notion, however, additional and more
elaborate analyses are necessary, employing e.g. trans-
genic mice, or cellular constructs in which the expression
of PP2Cα can both be induced and reduced conditionally.
Histological analyses of human tumor samples, intended
to (negatively) correlate the expression of the phosphatase
with the grade of malignancy, are also expected to contrib-
ute to our understanding of the role of PP2Cα in tumorMolecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
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suppression. And furthermore, PP2Cα-based therapeutic
interventions should be evaluated, using either the pro-
tein itself, or other means to enhance its expression and/
or its activity (e.g. plasmid DNA or low molecular weight
agonists). Besides merely increasing our knowledge on
the involvement of this type 2C phosphatase in inhibiting
tumor growth, such analyses may also give rise to new
therapeutic entities for treating advanced solid malignan-
cies, and they likely also lead to new insights on other
physiological functions of PP2Cα.
Conclusion
In summary, we here show that the siRNA-mediated
knockdown of PP2Cα does not affect the in vitro prolifer-
ation, the clonogenic survival, the membrane integrity
and the radio- and chemosensitivity of MCF7 cells. It
does, however, substantially reflect on their cell cycle dis-
tribution: for MCF7-si cells, the number of cells in G0/G1
was reduced, the induction of the G1 block was attenu-
ated, the number of cells in G2/M was increased and the
induction of the G2 block was enhanced. In addition, the
knockdown of PP2Cα affected the tumorigenic potential
and the in vivo proliferation of the MCF7 cells, which
were both found to be significantly higher for cells
expressing attenuated amounts of the protein. Based on
these findings, we conclude that PP2Cα plays a role in the
regulation of the cell cycle, in the induction of cell cycle
checkpoints and in tumor suppression.
Methods
Plasmid preparation
The pSUPER-Retro vector [31] was prepared for ligation
by double-cutting with HindIII and BglII enzymes, and by
purifying the linearized vector using agarose gels. Lyophi-
lized synthetic 64-basepair long DNA oligonucleotides
were dissolved in 50 µl of ultra-pure water. The oligonu-
cleotide sequences used were: I) PP2Cα-siRNA-forward:
5'-GATCCCCCACATGAGAGTTATGTCAGTTCAAG
AGACTGACATAACTCTCATGTGTTTTTGGAAA-3' (the
siRNA target sequence from the PP2Cα gene is under-
lined), and II) PP2Cα-siRNA-reverse: 5'-AGCT TTTC-
CAAAAACACATGAGAGTTATGTCAGTCTCTTGAACTGA
CATAACTCTCATGTGGGG-3'. One microliter of each oli-
gonucleotide was annealed in 48 µl of annealing buffer (4
min incubation at 95°C, 10 min at 70°C and slow cool-
ing to 4°C). Two microliters of the annealed oligos were
then phosphorylated at their 5'-end using 10 U of T4 poly-
nucleotide kinase (PNK; New England Biolabs). Before
ligation, the molar concentration of the purified vector
and of the phosphorylated oligos were determined. The
ligation was performed in a volume of 20 µl for 2 h at
room temperature, according to the manufacturer's
instructions, i.e. using 3 U of T4 DNA ligase (Promega)
and a 10–20-fold molar excess of the oligos. The ligation
product was directly transformed into competent cells.
The presence of the insert in growing colonies was con-
firmed using plasmid mini-preparation and double-cut-
ting with EcoRI and HindIII enzymes.
Cell transfection and tissue culture
Wild type MCF7 (human breast adenocarcinoma) cells
were obtained from ATCC. PP2Cα siRNA-expressing
MCF7 cells were prepared by growing wild type MCF7
cells to 50–70 % confluency, and by then transfecting
them with the abovementioned oligonucleotide-contain-
ing plasmid using Lipofectamine (Invitrogen). It should
be noted here that besides the polymerase-III H1-RNA
gene promoter and the genetic insert encoding for PP2Cα-
siRNA, the pSUPER-Retro vector also contains a puromy-
cin resistance gene, in order to allow for the selection of
positively transfected clones [31]. After 6 h of incubation
at 37°C, the transfection mixture was removed and it was
replaced with complete DMEM (Gibco), i.e. supple-
mented with 1% glutamine (Gibco) and 10% FCS
(Gibco). The siRNA-expressing cells were subsequently
grown for an additional 12 h, and from then on, the con-
centrations of puromycin (Sigma-Aldrich) were gradually
increased from 1 to 20 µg/ml. Several positively trans-
fected clones were obtained, and these were cultivated in
complete DMEM containing 20 µg/ml of the selection
agent.
Proliferation and viability assays
The doubling time of wild type and PP2Cα siRNA-
expressing MCF7 cells was determined by seeding 1 * 105
cells into 6-well plates (3 wells per time point). At several
time points after seeding, the cells were trypsinized and
harvested, and the number of cells in each well was quan-
tified using an automated cell counter (Coulter Counter
ZM). The proliferation of the cells upon treatment with
radio- and chemotherapy was determined by means of the
sulphorhodamine B (SRB) assay [32]; hereto, 1 * 105 cells
were seeded into 6-well plates and they were grown for 5–
8 days. Then the cells were fixed, stained and dried, the
SRB dye was extracted, it was transferred to a 96-well plate,
and the absorbance of each of the wells was analyzed
spectrophotometrically at 540 nm. The clonogenic sur-
vival of the cells was determined by means of the colony
formation assay (CFA); 2000 cells were seeded into 6-well
plates and they were grown for 10–14 days. Then, they
were fixed and stained with crystal violet, and the number
of colonies (i.e. spatially separated plagues consisting of at
least 50 cells) was counted. The membrane integrity of the
cells was investigated by quantifying the uptake of propid-
ium iodide (PI; a membrane-impermeable dye that only
enters and stains membrane-damaged and dead cells). 1 *
106 Cells were seeded into T75 culture flasks, and at sev-
eral time points post treatment, they were trypsinized,
harvested and incubated with PI. The uptake of PI was
analyzed on a FACS Calibur (Becton Dickinson).Molecular Cancer 2007, 6:65 http://www.molecular-cancer.com/content/6/1/65
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Cell cycle analysis
The cell cycle distribution of wild type and PP2Cα siRNA-
expressing MCF7 cells was determined by seeding 1 * 106
cells into T75 culture flasks. At several predefined time
points after seeding (and after radio- or chemotherapy),
the cells were trypsined, harvested, resuspended in 1 ml of
-20°C methanol and stored until analysis. Immediately
prior to analysis, the cells were washed with culture
medium and resuspended in 1 ml of PBS containing 0.1%
of NaN3. Then, 50 µg of PI were added to each vial and the
samples were analyzed on a FACS Calibur (Becton Dick-
inson).
Radio- and chemotherapy
Radiotherapy was applied by exposing the cells (in well-
plates or in culture flasks) to different doses of 60Cobalt γ-
radiation. Radiotherapy was delivered by means of the
Siemens Gammatron S, at a dose rate of 0.5 Gy/min. Dox-
orubicin was obtained from Sigma-Aldrich. Gemcitabine
was kindly provided by Eli Lilly. Both agents were of
appropriate analytical grade (>99.8%).
In vivo analysis
All experiments involving animals were approved by an
external committee for animal welfare and were per-
formed according to international and institutional
guidelines. The tumorigenicity of wild type and PP2Cα
knockdown MCF7 cells was investigated by inoculating 1
* 107 cells into both hind limbs of immunodeficient nude
mice. As both types of cells failed to develop tumors under
'standard' conditions, their tumorigenicity was also evalu-
ated upon the implementation of estrogen-containing
hormone pellets (0.36 mg 17β-Estradiol per pellet; Inno-
vative Research of America) and Matrigel (Matrigel Base-
ment Membrane Matrix; Becton Dickinson). The tumors
that developed upon the combined implementation of
hormone pellets and Matrigel were harvested at day 37
after inoculation. Both for MCF7-wt and for MCF7-si,
three animals that had developed tumors were injected
with BrdU 24 h before harvesting, and the incorporation
of the proliferation marker was analyzed by means of
FACS analysis.
Immunohistochemistry
Cryosections (6 µm) were prepared using the Leica Frig-
ocut 2800 E and they were fixed in methanol/acetone.
Prior to staining, the cryosections were blocked with the
Image-iT FX signal-enhancer (Molecular Probes) and/or
with 5% human serum albumin (HSA; Sigma-Aldrich).
Then, they were incubated for 1 h with a 1/100 dilution of
rabbit anti-PP2Cα (3S1; Prepared at Tel Aviv University
[10,11]), or with a 1/50 dilution of rabbit anti-Ki-67 (Pro-
liferation marker; sc-15402; Santa Cruz). Upon three PBS
washes, the sections were incubated with a 1/100 dilution
of donkey anti-rabbit Alexa-Fluor-488 (A21206; Molecu-
lar Probes), or with a 1/250 dilution of goat anti-rabbit-
HRP (P0448; DakoCytomation). Nuclear counterstaining
was performed using DAPI or Haematoxilyn. 3-Amino-9-
ethylcarbazole (AEC) was used as an HRP-responsive dye
for light microscopy.
Statistical analysis
All values are expressed as average ± standard deviation.
The two-tailed Student's t-test was used to assess if the dif-
ferences between the various experimental groups were
significant. P < 0.05 was considered to represent statistical
significance.
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